secwatch / observer
8-K filed October 18, 2023, 7:59 PM ET CIK 0001538210
other material confidence high sentiment neutral materiality 0.70

NexImmune announces 1-for-25 reverse stock split effective Oct 18, 2023 to regain Nasdaq compliance

NexImmune, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NexImmune, Inc.: Reverse stock split at 1-for-25 ratio, effective after close of trading on October 18, 2023 (effective 2023-10-18).

Change
charter amendment
Effective
2023-10-18
Exact text from the filing
On October 18, 2023, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to effect a one-time reverse stock split of the Company’s common stock, at a ratio of 1-for-25 (the “Reverse Stock Split”). The Reverse Stock Split was effective at 5 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on October 18, 2023 (the “Effective Time”).
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

NexImmune, Inc. shareholders approved Approval of adjournment of the special meeting to solicit additional proxies if necessary. at the 2023-10-17 meeting.

Outcome
passed
Meeting
2023-10-17
Exact text from the filing
Votes For Votes Against Votes Abstained 13,899,330 286,293 88,853
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

NexImmune, Inc. shareholders approved Approval of amendment to certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-4 and not more than 1-for-50, with exact ratio set by board. at the 2023-10-17 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2023-10-17
Exact text from the filing
Votes For Votes Against Votes Abstained 13,838,206 344,220 92,050
View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR
accession 0001193125-23-258490
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.